This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ODM201, BAY 1841788, BAY-1841788, BAY1841788
Description: ODM-201 is an androgen receptor antagonist.
Orion and Endo
Orion is jointly developing ODM-201 with Endo Pharmaceuticals.
In October 2013, the collaboration agreement with Endo Pharmaceuticals concerning development of ODM-201 has been terminated and subject to an ongoing royalty obligation due to Endo, all rights to ODM-201 revert to Orion.
Bayer and Orion
In June 2014, Bayer and Orion entered into a global agreement for the development and commercialization of ODM-201. Under the terms of the agreement, Bayer and Orion will jointly develop ODM-201, with Bayer contributing a major share of the costs of future development. Bayer will commercialize ODM-201 globally and Orion has the option to co-promote ODM-201 in Europe. Orion will be responsible for the manufacturing of the product. Orion will receive an upfront payment of EUR 50 million and is eligible to receive cash payments from Bayer upon achievement of certain development, tech transfer and commercialization milestones, as well as...See full deal structure in Biomedtracker
Partners: Endo International plc Orion Corporation
Additional information available to subscribers only: